Fetal Blood Groups and Hemolytic Disease of the Fetus and Newborn (HDFN)

In cases of Rh incompatibility, an Rh-negative mother may develop antibodies against an Rh-positive fetus’s red blood cells if their blood mixes, a process known as alloimmunization. This can occur during delivery, miscarriage, abortion, invasive procedures (e.g., amniocentesis), or trauma.

Alloimmunization can lead to hemolytic disease of the fetus and newborn (HDFN). In this serious condition, maternal antibodies attack fetal red blood cells, causing anemia, jaundice, or, in severe cases, hydrops fetalis (fluid buildup in the fetus) or stillbirth. The risk is typically low in the first pregnancy but increases in subsequent pregnancies if the mother becomes sensitized.

To monitor HDFN, additional tests may be required, including ultrasounds to assess fetal anemia or organ enlargement and, in rare cases, fetal blood sampling via the umbilical cord. Early identification and management are critical to improving outcomes.

RhoGAM and Its Indications

RhoGAM (RhIG), a brand of Rh immunoglobulin, is a vital tool for preventing Rh alloimmunization. It works by neutralizing Rh-positive fetal red blood cells in a Rh-negative mother’s bloodstream, preventing her immune system from producing antibodies. It is a safe blood product with minimal side effects, such as mild soreness at the injection site or a slight fever. It does not cross the placenta or harm the fetus. However, informed consent is required before administration, as it is derived from human plasma. More importantly, once a mother is sensitized, RhIG is no longer effective, and complications may arise.

As previously mentioned, any event where the fetal and maternal bloods might be mixed presents the risk of alloimmunization and adverse events. As a result, the following are generally considered indications for RhoGAM administration:

• Routine antepartum prophylaxis: As a preventive measure, Rh-negative, non-sensitized women (first pregnancy with a possibly Rh-positive fetus) should receive a dose of RhIG at 28 weeks of gestation to prevent sensitization during the third trimester, when minor feto-maternal hemorrhage (bleeding) is more likely.
• Postpartum administration: If the baby is confirmed to be Rh-positive after delivery, the mother should receive another dose of RhIG within 72 hours to protect future pregnancies.
• After a potential feto-maternal hemorrhage: RhIG is indicated within 72 hours of events that may cause blood mixing, such as:

• Miscarriage, stillbirth, or ectopic pregnancy
• Invasive procedures (e.g., amniocentesis, chorionic villus sampling)
• Trauma to the abdomen (e.g., from a fall or accident)
• External cephalic version (a procedure to turn a breech baby)
• Placental abruption or bleeding

Recent Advances and Initiatives in Ontario

Ontario is at the forefront of improving prenatal care through initiatives like the Better Outcomes Registry and Network (BORN) Ontario. The introduction of fetal blood group genotyping, set to expand in 2025, will allow for more precise administration of RhIG, reducing unnecessary injections for Rh-negative mothers carrying Rh-negative fetuses. This advancement not only enhances patient safety but also optimizes healthcare resources.

Conclusion

Blood group incompatibility, particularly Rh incompatibility, is a manageable condition with proper prenatal care. By understanding the roles of maternal, paternal, and fetal blood groups and adhering to recommended testing and RhIG administration protocols, the risks of complications, like HDFN, can be significantly reduced. 

For more detailed and reliable information on pregnancy care, consult your healthcare provider and seek more information to make the best decision about your journey in collaboration with your care provider, such as your family physician, registered practical nurse, midwife, or obstetrician.

Please feel free to share your experience or concerns with us in the comment section or fill out our online questionnaire.